Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/13678
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPoh, Ashleigh Ren
dc.contributor.authorO'Donoghue, Robert J Jen
dc.contributor.authorErnst, Matthiasen
dc.date2015-06-10en
dc.date.accessioned2015-06-29T23:05:05Z-
dc.date.accessioned2015-07-15T01:16:21Z-
dc.date.available2015-06-29T23:05:05Z-
dc.date.available2015-07-15T01:16:21Z-
dc.date.issued2015-06-30en
dc.identifier.citationOncotarget 2015; 6(18): 15751-15771en
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/13678en
dc.description.abstractThe hematopoietic cell kinase (HCK) is a member of the SRC family of cytoplasmic tyrosine kinases (SFKs), and is expressed in cells of the myeloid and B-lymphocyte cell lineages. Excessive HCK activation is associated with several types of leukemia and enhances cell proliferation and survival by physical association with oncogenic fusion proteins, and with functional interactions with receptor tyrosine kinases. Elevated HCK activity is also observed in many solid malignancies, including breast and colon cancer, and correlates with decreased patient survival rates. HCK enhances the secretion of growth factors and pro-inflammatory cytokines from myeloid cells, and promotes macrophage polarization towards a wound healing and tumor-promoting alternatively activated phenotype. Within tumor associated macrophages, HCK stimulates the formation of podosomes that facilitate extracellular matrix degradation, which enhance immune and epithelial cell invasion. By virtue of functional cooperation between HCK and bona fide oncogenic tyrosine kinases, excessive HCK activation can also reduce drug efficacy and contribute to chemo-resistance, while genetic ablation of HCK results in minimal physiological consequences in healthy mice. Given its known crystal structure, HCK therefore provides an attractive therapeutic target to both, directly inhibit the growth of cancer cells, and indirectly curb the source of tumor-promoting changes in the tumor microenvironment.en
dc.subjectSRC family kinasesen
dc.subjectHematopoietic cell kinaseen
dc.subjectCanceren
dc.subjectLeukemiaen
dc.subjectSFK inhibitorsen
dc.titleHematopoietic cell kinase (HCK) as a therapeutic target in immune cancer cellsen
dc.typeJournal Articleen
dc.identifier.journaltitleOncotargeten
dc.identifier.affiliationWalter and Eliza Hall Institue of Medical Research, Department of Medical Biology, University of Melbourne, Victoriaen
dc.identifier.affiliationOlivia Newton-John Cancer Research Institute, La Trobe University School of Cancer Medicine, Victoria, Australiaen
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/26087188en
dc.type.contentTexten
dc.identifier.orcid0000-0002-6399-1177-
dc.type.austinJournal Articleen
item.fulltextWith Fulltext-
item.openairetypeJournal Article-
item.cerifentitytypePublications-
item.grantfulltextopen-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Files in This Item:
File Description SizeFormat 
Ernst M (2015) Hematopoietic cell kinase.pdf2.63 MBAdobe PDFThumbnail
View/Open
Show simple item record

Page view(s)

6
checked on Jan 27, 2023

Download(s)

2
checked on Jan 27, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.